Bacillus subtilis fermentation fraction and preparation method therefor
By using a method for preparing fermentation fractionation products of Bacillus subtilis, fermentation products with different molecular weight ranges were separated, solving the problem of toxic side effects in clinical drug use, achieving safe and effective fibrinolytic, thrombolytic, blood pressure lowering, and blood lipid lowering effects, and realizing green manufacturing.
Patent Information
- Application Number
- PCT/CN2023/103808
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2023-06-29
- Publication Date
- 2024-11-28
AI Technical Summary
Existing clinical medications are mainly small molecule chemical drugs, which have toxic side effects with long-term use. There is a lack of safe and effective functional foods and drugs.
The preparation method of fermentation fractionation products of Bacillus subtilis was adopted. Fermentation products A, B, C and D with different molecular weight ranges were obtained by fractionation separation. Fermentation product A has a molecular weight greater than 10,000 Da, fermentation product B has a molecular weight of 6,000 Da-10,000 Da, fermentation product C has a molecular weight of 2,000 Da-6,000 Da, and fermentation product D has a molecular weight of 100 Da-2,000 Da. By utilizing the specific molecular weight range and bioactivity of these products, the effects of fibrinolysis, thrombolysis, improving immunity, lowering blood pressure and lowering blood lipids can be achieved.
Fermentation product A has significant fibrinolytic and thrombolytic effects, fermentation product B helps improve immunity, fermentation product C has a blood pressure lowering effect, and fermentation product D has significant effects on lowering blood lipids and treating fatty liver. Furthermore, it achieves zero discharge and green manufacturing of fermentation water.
Smart Images

Figure CN2023103808_28112024_PF_FP_ABST
Abstract
Description
Bacillus subtilis fermentation graded product and preparation method thereof Technical Field
[0001] The invention relates to the field of Bacillus subtilis fermentation, and in particular to a Bacillus subtilis fermentation graded product and a preparation method thereof. Background Art
[0002] The current prevalence of cardiovascular disease in my country is extremely severe, with over 450 million people suffering from it. Thrombotic disease, hypertension, and hyperlipidemia are among the most serious cardiovascular diseases, severely impacting people's health and quality of life. However, current clinical medications are primarily small-molecule chemical drugs, which can have various toxic side effects with long-term use, and there is a lack of safe and effective functional foods and drugs. Technical issues
[0003] The present application provides a Bacillus subtilis fermentation graded product and a preparation method thereof, in order to solve the technical problem that current clinical drugs are mainly small molecule chemical drugs, which have various toxic side effects when taken for a long time, and lack safe and effective functional foods and drugs. Solution
[0004] The present invention provides a method for preparing a fractionated product of Bacillus subtilis fermentation, which comprises:
[0005] Step 1), preparing fermentation medium;
[0006] Step 2), inoculating the Bacillus subtilis strain into the fermentation medium of step 1) to obtain a seed solution;
[0007] Step 3) inoculating the seed solution obtained in step 2) into a fermentation medium at an inoculum rate of 1%-5% to obtain a fermentation liquid. The fermentation conditions are as follows: fermentation time of 18-22 hours, fermentation temperature of 36-38° C., and dissolved oxygen content of 20-40% in the fermentation environment.
[0008] Step 4), after the fermentation is completed, the fermentation liquid obtained in step 3) is separated to obtain bacterial cells and fermentation liquid;
[0009] In step 5), the fermentation broth obtained in step 4) is subjected to fractional separation to collect a plurality of fermentation products with different molecular weight ranges, namely, fermentation product A with a molecular weight greater than 10,000 Da, fermentation product B with a molecular weight of 6,000 Da to 10,000 Da, fermentation product C with a molecular weight of 2,000 Da to 6,000 Da, and fermentation product D with a molecular weight of 100 Da to 2,000 Da.
[0010] In the method for preparing a fractionated fermentation product of Bacillus subtilis of the present application, in step 1), the fermentation medium contains 1%-5% by mass of a nitrogen source, 2%-4% by mass of glucose, and 0.01%-0.1% by mass of calcium sulfate.
[0011] In the preparation method of the Bacillus subtilis fermentation fractionated product of the present application, the nitrogen source is soybean component.
[0012] In the method for preparing the Bacillus subtilis fermentation fractionation product of the present application, in the step 2), the fermentation temperature is 35-40° C., the shaking speed is 100-500 r / min, and the culture time is 15-20 h.
[0013] In the preparation method of the Bacillus subtilis fermentation fractionated product of the present application, before inoculating the Bacillus subtilis strain into the fermentation medium in step 1), it is activated with a fresh slant for 18-24 hours, and a loop of Bacillus subtilis cells is picked from the slant for inoculation.
[0014] In the preparation method of the Bacillus subtilis fermentation graded product of the present application, in step 4), the fermentation liquid obtained in step 3) is separated by a tubular centrifuge, the bacterial sludge is collected, mixed with water at a weight ratio of 1:20, 10% maltodextrin is added, and spray drying is performed to obtain bacterial cells.
[0015] In the preparation method of the Bacillus subtilis fermentation fractionated product of the present application, in step 4), the drying process is: inlet air temperature 155° C., outlet air temperature 82° C., and feed rate 25 r / min.
[0016] In the method for preparing the fractionated fermentation products of Bacillus subtilis of the present application, in step 5), the fermentation broth obtained in step 4) is separated and collected by a separation process to obtain a plurality of fermentation products with different molecular weight ranges, specifically comprising:
[0017] The fermentation broth is concentrated by ultrafiltration using a 10,000 Da separation membrane to obtain a concentrate A, and the concentrate A is subjected to vacuum freeze drying or spray drying to obtain a fermentation product A having a molecular weight greater than 10,000 Da;
[0018] The permeate obtained by ultrafiltration with a 10,000 Da separation membrane in the previous step is concentrated by ultrafiltration with a 6,000 Da separation membrane to obtain a concentrate B, and the concentrate B is freeze-dried or spray-dried to obtain a fermentation product B with a molecular weight of 6,000 Da to 10,000 Da;
[0019] The permeate obtained by ultrafiltration through a 6000Da separation membrane in the previous step is concentrated through a 2000Da separation membrane ultrafiltration device to obtain a concentrate C, and the concentrate C is vacuum freeze-dried or spray-dried to obtain a fermentation product C with a molecular weight of 2000Da-6000Da;
[0020] The permeate from the 2000Da separation membrane ultrafiltration in the previous step is concentrated through a 100Da separation membrane ultrafiltration device to obtain a concentrated solution D, and the concentrated solution D is vacuum freeze-dried or spray-dried to obtain a fermentation product D with a molecular weight of 100Da-2000Da.
[0021] In the method for preparing the fractionated fermentation product of Bacillus subtilis of the present application, in step 5), the permeate concentrated by the 100Da separation membrane ultrafiltration device can be used to prepare the fermentation medium.
[0022] The present application also proposes a method for preparing a fractionated product of Bacillus subtilis fermentation, which comprises:
[0023] Step 1), preparing fermentation medium;
[0024] Step 2), inoculating the Bacillus subtilis strain into the fermentation medium of step 1) to obtain a seed solution;
[0025] Step 3) inoculating the seed solution obtained in step 2) into a fermentation medium at an inoculum rate of 1%-5% to obtain a fermentation liquid;
[0026] Step 4), after the fermentation is completed, the fermentation liquid obtained in step 3) is separated to obtain bacterial cells and fermentation liquid;
[0027] In step 5), the fermentation broth obtained in step 4) is subjected to fractional separation to collect a plurality of fermentation products with different molecular weight ranges, namely, fermentation product A with a molecular weight greater than 10,000 Da, fermentation product B with a molecular weight of 6,000 Da to 10,000 Da, fermentation product C with a molecular weight of 2,000 Da to 6,000 Da, and fermentation product D with a molecular weight of 100 Da to 2,000 Da.
[0028] In the method for preparing a fractionated fermentation product of Bacillus subtilis of the present application, in step 1), the fermentation medium contains 1%-5% by mass of a nitrogen source, 2%-4% by mass of glucose, and 0.01%-0.1% by mass of calcium sulfate.
[0029] In the preparation method of the Bacillus subtilis fermentation fractionated product of the present application, the nitrogen source is soybean component.
[0030] In the method for preparing the Bacillus subtilis fermentation fractionation product of the present application, in the step 2), the fermentation temperature is 35-40° C., the shaking speed is 100-500 r / min, and the culture time is 15-20 h.
[0031] In the preparation method of the Bacillus subtilis fermentation fractionated product of the present application, before inoculating the Bacillus subtilis strain into the fermentation medium in step 1), it is activated with a fresh slant for 18-24 hours, and a loop of Bacillus subtilis cells is picked from the slant for inoculation.
[0032] In the preparation method of the Bacillus subtilis fermentation graded product of the present application, in step 4), the fermentation liquid obtained in step 3) is separated by a tubular centrifuge, the bacterial sludge is collected, mixed with water at a weight ratio of 1:20, 10% maltodextrin is added, and spray drying is performed to obtain bacterial cells.
[0033] In the preparation method of the Bacillus subtilis fermentation fractionated product of the present application, in step 4), the drying process is: inlet air temperature 155° C., outlet air temperature 82° C., and feed rate 25 r / min.
[0034] In the method for preparing the fractionated fermentation products of Bacillus subtilis of the present application, in step 5), the fermentation broth obtained in step 4) is separated and collected by a separation process to obtain a plurality of fermentation products with different molecular weight ranges, specifically comprising:
[0035] The fermentation broth is concentrated by ultrafiltration using a 10,000 Da separation membrane to obtain a concentrate A, and the concentrate A is subjected to vacuum freeze drying or spray drying to obtain a fermentation product A having a molecular weight greater than 10,000 Da;
[0036] The permeate obtained by ultrafiltration with a 10,000 Da separation membrane in the previous step is concentrated by ultrafiltration with a 6,000 Da separation membrane to obtain a concentrate B, and the concentrate B is freeze-dried or spray-dried to obtain a fermentation product B with a molecular weight of 6,000 Da to 10,000 Da;
[0037] The permeate obtained by ultrafiltration through a 6000Da separation membrane in the previous step is concentrated through a 2000Da separation membrane ultrafiltration device to obtain a concentrate C, and the concentrate C is vacuum freeze-dried or spray-dried to obtain a fermentation product C with a molecular weight of 2000Da-6000Da;
[0038] The permeate from the 2000Da separation membrane ultrafiltration in the previous step is concentrated through a 100Da separation membrane ultrafiltration device to obtain a concentrated solution D, and the concentrated solution D is vacuum freeze-dried or spray-dried to obtain a fermentation product D with a molecular weight of 100Da-2000Da.
[0039] In the method for preparing the fractionated fermentation product of Bacillus subtilis of the present application, in step 5), the permeate concentrated by the 100Da separation membrane ultrafiltration device can be used to prepare the fermentation medium.
[0040] The present application also proposes a Bacillus subtilis fermentation fractionated product, wherein the Bacillus subtilis fermentation fractionated product is prepared by the above-mentioned preparation method of the Bacillus subtilis fermentation fractionated product.
[0041] The fractionated products of Bacillus subtilis fermentation in the present application include fermentation product A with a molecular weight greater than 10,000 Da, fermentation product B with a molecular weight of 6,000 Da-10,000 Da, fermentation product C with a molecular weight of 2,000 Da-6,000 Da, and fermentation product D with a molecular weight of 100 Da-2,000 Da. Beneficial effects
[0042] The present invention uses separation technology to collect components of different molecular weight ranges in steps and stages, namely fermentation product A with a molecular weight greater than 10,000 Da, fermentation product B with a molecular weight of 6,000-10,000 Da, fermentation product C with a molecular weight of 2,000-6,000 Da, and fermentation product D with a molecular weight of 100-2,000 Da. The four fermentation products have different effects. Among them, fermentation product A has a molecular weight greater than 10,000 and contains Bacillus subtilis fibrinolytic enzyme. Its molecular weight is about 28,000 and has fibrinolytic and thrombolytic effects. Fermentation product B has a molecular weight of 6,000-10,000 and helps improve immunity. It contains intact molecular proteins and protein fragments in this range, and small molecular proteins have the effect of improving immunity. Fermentation product C has a molecular weight in the range of 2,000-6,000 and contains very few small molecular intact proteins. The majority of polypeptides reported in the literature to have blood pressure-lowering effects are concentrated in this molecular weight range. The molecular weight of fermentation product D is in the range of 100-2000, which is the main distribution range of short peptides with lipid-lowering function discovered for the first time in the present invention. It has significant lipid-lowering effect and fatty liver treatment effect, and has been identified by amino acid sequencing. At the same time, the present invention uses separation process technology to ultimately achieve that the water quality of the permeate meets the fermentation water standard after testing, and can be recycled for the configuration of the next batch of bacterial fermentation culture medium, thereby achieving zero wastewater discharge and green manufacturing of fermentation products. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] FIG1 is the HE staining results of the inferior vena cava sections of SD rats subjected to oral administration of fermentation product A for 14 days in Experiment 1 of the present invention.
[0044] FIG2 is a schematic diagram of the serum TG content of mice in Experiment 4 of the present invention.
[0045] FIG3 is an Oil Red O-stained pathological tissue section of mouse liver in Experiment 4 of the present invention. Modes for Carrying Out the Invention
[0046] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the embodiments described are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without making creative efforts are within the scope of protection of this application.
[0047] Preparation plan 1
[0048] The present application proposes a method for preparing a fractionated product of Bacillus subtilis fermentation, comprising the steps of:
[0049] Step 1) preparing a fermentation medium;
[0050] The fermentation medium contains 2% by mass of soybean meal powder, 3% by mass of glucose and 0.02% by mass of calcium sulfate; the nitrogen source is soybean;
[0051] Step 2) preparing seed solution;
[0052] Before use, activate the Bacillus subtilis strain on a fresh slant for 18-24 hours. Then, pick a loopful of Bacillus subtilis cells from the slant for inoculation. Inoculate 1-5 loopfuls of seed Bacillus subtilis into 600 ml of the fermentation medium from step 1). Incubate at 37°C, 200 rpm, and shake for 18 hours to obtain the seed solution. Sterilize at 110-115°C for 20 minutes.
[0053] The Bacillus subtilis ZF01 has a deposit number of CCTCC NO: M2022132, is deposited in the China Center for Type Culture Collection, is classified as Bacillus subtilis, has a deposit date of February 18, 2022, and is deposited at Wuhan University, China.
[0054] Step 3) inoculation and fermentation;
[0055] Inoculate 600ml of the seed solution into a fermentation tank containing 30L of culture medium at a 2% inoculum volume. Control the temperature at 37°C, adjust the speed and dissolved oxygen (DO) to 30%, and ferment for 20-21 hours. After fermentation, obtain the fermentation broth.
[0056] Step 4) bacterial liquid separation;
[0057] After fermentation is complete, the fermentation broth obtained in step 3) is separated by a tubular centrifuge. The bacterial sludge is collected and mixed with water at a weight ratio of 1:20. 10% maltodextrin is added, and the bacterial cells are spray-dried. The drying process uses an inlet air temperature of 155°C, an outlet air temperature of 82°C, and a feed rate of 25 r / min. The dried Bacillus subtilis powder can be developed into edible fungi or probiotics. After removing the bacterial cells from the fermentation broth, approximately 25 L of fermentation supernatant is obtained.
[0058] Step 5) Fermentation broth is graded and collected;
[0059] The fermentation broth obtained in step 4) is separated and collected through a separation process to obtain a variety of fermentation products with different molecular weight ranges, specifically including:
[0060] The fermentation broth is ultrafiltered and concentrated through a 10,000 Da separation membrane ultrafiltration device to obtain approximately 2.5 L of concentrate A and approximately 22 L of permeate. The concentrate A is then freeze-dried or spray-dried to obtain a fermentation product A having a molecular weight greater than 10,000 Da.
[0061] The 22 L permeate from the previous step was concentrated through a 6000 Da separation membrane ultrafiltration device to obtain about 2.2 L of concentrate B and about 20 L of permeate. The concentrate B was vacuum freeze-dried or spray-dried to obtain a fermentation product B with a molecular weight of 6000 Da to 10000 Da.
[0062] The 20 L permeate from the previous step is concentrated through a 2000 Da separation membrane ultrafiltration device to obtain approximately 2 L of concentrate C and approximately 18 L of permeate. Concentrate C is then freeze-dried or spray-dried to obtain fermentation product C with a molecular weight of 2000 Da to 6000 Da.
[0063] The 18 L permeate from the previous step was concentrated through a 100 Da membrane ultrafiltration device to yield approximately 1.8 L of concentrate D, with approximately 16 L of permeate. Concentrate D was then freeze-dried or spray-dried to yield fermentation product D with a molecular weight of 100 Da to 2000 Da. The permeate, concentrated through the 100 Da membrane ultrafiltration device, can be used to prepare fermentation medium.
[0064] Experiment 1: Testing of the fibrinolytic activity and thrombolytic efficacy of fermentation product A
[0065] 1.1. Fibrinolytic activity assay of fermentation product A
[0066] (1) Reagent preparation
[0067] Solution A: Weigh 121.1g of Tris and dissolve in water. Adjust the pH to 8.0 with approximately 42ml of concentrated hydrochloric acid. Finally, dilute to 1L to create the mother solution. Take 10ml of the mother solution and dilute to 500ml with water to create Solution A.
[0068] Solution B: Weigh 9g of NaCl, add water to dissolve it, and adjust the volume to 1L.
[0069] 50mg / ml fibrinogen solution: Weigh 1g of fibrinogen powder and dissolve it in 20ml of solution A until it is fully dissolved.
[0070] 100U / ml thrombin solution: Dissolve 1000U thrombin in 10ml solution A and allow it to dissolve completely.
[0071] Urokinase standard solution: Dissolve the urokinase standard (1240 IU / vial) in 2 ml of sterile saline (0.9% W / V) to make a 620 IU / ml solution. Transfer 1 ml of this solution to another vial containing 1 ml of saline to make a 310 IU / ml solution. Dilute this solution sequentially to 155 IU / ml, 77.5 IU / ml, 38.75 IU / ml, and 19.375 IU / ml of standard urokinase solutions for later use.
[0072] (2) Experimental methods
[0073] Preparation of fibrin plate: Weigh 0.15 g agar (0.75%) and 0.1755 g NaCl (0.15 M) and add to a 50 ml small conical flask. Dissolve the agar in 20 ml of Solution A. Stopper the conical flask and place it in a microwave oven to dissolve. When the conical flask cools to 50°C, add 1 ml of 50 mg / ml fibrinogen solution and 100 µl of 100 U / ml thrombin to the flask. Mix thoroughly and quickly pour into a sterile plate. Let stand at room temperature for 30 minutes to form a fibrin clot.
[0074] Preparation of test sample solutions: Dissolve an appropriate amount of the test sample in Solution B and dilute to a concentration within the standard curve range. Construct a urokinase standard curve: Use a microporator to punch seven wells on a fibrin plate and label them. Dispense 10µl of the standard urokinase solution of each concentration into the corresponding wells. Allow to react for 10 minutes before transferring to a 37°C incubator. After 18 hours, measure the two perpendicular diameters of each dissolution zone. Perform this procedure in triplicate and average the measurements. Construct a urokinase activity standard curve using the common logarithm of the product of the perpendicular diameters (S) as the horizontal axis and the common logarithm of the standard urokinase concentration as the vertical axis. Determination of thrombolytic activity of the test sample: Load 10µl of the test sample onto the same plate as above and incubate at 37°C. After 18 hours, measure the two perpendicular diameters of the dissolution zone. Calculate the enzyme activity of the sample using the standard curve method and the dilution concentration.
[0075] The experimental results showed that the fibrinolytic activity of fermentation product A with a molecular weight greater than 10,000 Da was finally measured to be 418,000 IU / g.
[0076] 1.2. Thrombolytic Efficacy Test of Fermentation Product A
[0077] Experimental methods: 46 male SD rats were randomly divided into 5 groups, namely sham operation group (6 rats), thrombosis model control group (0 IU / kg) (10 rats), low-dose plasmin group (4000 IU / kg) (10 rats), medium-dose group (8000 IU / kg) (10 rats) and high-dose group (16000 IU / kg) (10 rats). The rats were orally gavaged twice a day with a dosing volume of 10 mL / kg. The thrombosis model control group was given the same volume of sodium chloride injection; half of the rats were dissected after 7 days of administration, and the rest were dissected after 14 days of administration. The 1.5 cm of the inferior vena cava below the ligature was placed in normal saline, quickly blotted dry with absorbent paper, and weighed to record the wet weight of the thrombus (vascular + intraluminal thrombus), and then fixed overnight with 4% paraformaldehyde for histological analysis.
[0078] Observation indicators: thrombus shape, size and weight, and vascular HE staining.
[0079] Experimental results: During the experiment, no animals in each group were found to be dying or dying; clinical observation results showed that no obvious abnormalities were found in the animals in each dose group and the model group.
[0080] The results of thrombus weight showed that there was no thrombus in the sham operation group. Compared with the model group, the weight of thrombus in the 7-day oral administration group, the weight of thrombus in the low-dose group (4000IU / kg), the medium-dose group (8000IU / kg) and the high-dose group (16000IU / kg) was significantly reduced, which were reduced by 17.45mg, 53.1mg and 64.47mg respectively; in the 14-day oral administration group, the weight of thrombus in the low-dose group (4000IU / kg), the medium-dose group (8000IU / kg) and the high-dose group (16000IU / kg) were significantly reduced, which were reduced by 21.26mg, 31.2mg and 40.16mg respectively, all of which were statistically different (p<0.05), and there was a dose-related phenomenon.
[0081] The results in Figure 1 show that HE staining of the blood vessels in the 14-day oral administration group showed that the structures of the blood vessels in the sham operation group were clear, the lumen was clean, and no obvious abnormalities were found; the main body of the blood vessels in the model group was basically necrotic and calcified, and the blood vessels were severely damaged; in the low-dose group (4000IU / kg), the peripheral blood vessels were basically necrotic and calcified, and narrow recanalized blood vessels were formed around them, which was slightly improved compared with the model group; in the medium-dose group (8000IU / kg), the thrombus in the blood vessel was recanalized, the thrombus was partially dissolved and cracks appeared, and the surrounding new endothelial cells grew in and covered the surface of the cracks to form new blood vessels, which was significantly improved compared with the model group; in the high-dose group (16000IU / kg), the blood vessel wall structure was intact, the structures of each layer were clear, and only small clusters of dissolved thrombi were seen in the lumen, mainly composed of red blood cells, fibrin and a small amount of white blood cell tissue, which was significantly improved compared with the model group.
[0082] Experimental conclusion: Under the experimental conditions, when rats were orally gavaged with fermentation product A (4000, 8000 and 16000 IU / kg) with a molecular weight greater than 10000 Da for 7 and 14 days, the effective thrombolytic dose was 4000 IU / kg, and the thrombolytic effect was better with increasing dose.
[0083] Experiment 2: Experiment on the efficacy of fermentation product B in improving immunity
[0084] Immunodeficiency Mouse Model: Fifty male mice (SPF grade) were randomly divided into five groups, with 10 animals in each group. These included a normal control group, an immunodeficiency model group, and low-, medium-, and high-dose groups (50 mg / kg⁻¹, 100 mg / kg⁻¹, and 200 mg / kg⁻¹) of the 6,000-10,000 Da fermentation product. The immunodeficiency model group received 10 consecutive intraperitoneal injections of 20 mg / kg⁻¹ / d⁻¹ of dexamethasone every other day to establish an immunodeficiency model. The normal control group received an equal volume of saline. Oral gavage with the fermentation product began the day after the first dexamethasone injection and continued for four weeks. The normal and model groups received an equal volume of saline.
[0085] After the experiment, the mice were weighed, their thymus and spleen were removed and weighed, and the thymus and spleen indices were calculated. The results are shown in the table. The thymus and spleen indices in the low, medium, and high dose groups were significantly higher than those in the model group, demonstrating that the 6,000-10,000Da fermentation product has the ability to enhance immunity.
[0086] Table 1 Effects of fermentation product B on immunocompromised mice
[0087] Group Thymus index Spleen index Normal group 0.1223±0.041 0.3145±0.0444 Model group 0.0098±0.0060 0.1380±0.0113 Low-dose group 0.0187±0.0098* 0.1512±0.0134* Medium-dose group 0.0375±0.0122** 0.1759±0.0237* High-dose group 0.0571±0.0241** 0.2007±0.0311*
[0088] *: P < 0.05 indicates significant difference, **: P < 0.01 indicates extremely significant difference
[0089] Experiment 3: Antihypertensive efficacy test of fermentation product C
[0090] Experimental methods: Spontaneously hypertensive rats (SHR), male, clean grade, 10-12 weeks old, weighing 200-220g. One week before the start of the experiment, the rats were subjected to non-invasive blood pressure measurement for one week to adapt to the measurement environment. 50 spontaneously hypertensive rats were divided into 5 groups, 10 rats in each group, and the model control group was gavaged with normal saline. The positive drug captopril group was given a rat dosage of 0.25mg according to the human daily dose conversion. The fermentation product C dosage was divided into three low, medium and high dosage groups of 50mg, 100mg and 200mg respectively. 10 Wistar rats, 200-220g, SPF grade, served as the ordinary control group and were gavaged with normal saline.
[0091] The medium dose of 0.5 g / kg.d was administered, the desired concentration was prepared with purified water as the solvent, and each rat was gavaged at 1.0 mL / 100 g.bw. The model control group was gavaged with purified water, and the normal control group was administered with the high dose of 1 g / kg.d according to Example 1, the desired concentration was prepared with purified water as the solvent, and each rat was gavaged at 1.0 mL / 100 g.bw. The administration was continued for 4 weeks.
[0092] Systolic blood pressure in rats was measured using an intelligent non-invasive sphygmomanometer. While the rats were awake and quiet, they were secured in a dedicated holder and preheated at 40°C for approximately 10 minutes to promote effective dilation of the tail artery and smooth blood flow. A pressure sensor was then inserted at the base of the rat's tail. Blood pressure, heart rate, and body weight were measured weekly during the experimental period, before, and after treatment.
[0093] SPSS statistical software was used for data processing, and t-test was used to analyze the significant differences between the groups. P < 0.05 was considered a significant difference, and P < 0.01 was considered an extremely significant difference. All test index data are expressed as mean ± standard deviation.
[0094] Table 2 Effects of fermentation product C on systolic blood pressure in experimental rats
[0095] Before administration / mmHgAfter 4 weeks of administration / mmHgNormal animal group136.6±2.3137.1±1.8Model control group174.4±5.6178.3±6.2Captopril group176.2±5.1141.2±6.7**Low-dose group174.1±5.5163.9±4.2*Middle-dose group172.8±5.7159.5±5.6**High-dose group174.7±6.3146.2±5.2**
[0096] *: P < 0.05 indicates significant difference, **: P < 0.01 indicates extremely significant difference
[0097] The test results are shown in Table 2. Compared with before administration, the three dose groups of low, medium and high significantly reduced the systolic blood pressure of rats, and the antihypertensive effect of the high dose group was basically consistent with that of the positive drug captopril, proving that the 2000Da-6000Da peptide powder has a very good blood pressure lowering effect.
[0098] Experiment 4: Fermentation product D for lowering blood lipids and treating fatty liver
[0099] Experimental Methods: Sixty male Kunming mice, weighing 20 ± 2 g, were randomly divided into six groups of 10 mice each. Fermentation product D was administered orally at low, medium, and high doses of 10 mg / mouse, 50 mg / mouse, and 100 mg / mouse. A statin-positive group (0.1 mg / mouse) was also administered. A fatty liver model group and a normal control group were also administered.
[0100] Except for the normal control group, which was fed the same ordinary feed, the other groups were fed a high-fat feed at 20-25°C for 4 weeks, during which they were given drugs by gavage every day. The fatty liver model group and the normal control group were gavaged with an equal volume of normal saline.
[0101] Observation indicators: Four blood lipid profiles: high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), and total cholesterol (CHO). Liver pathology of mice (HE staining).
[0102] Figure 2 shows the serum TG content of mice; B. the serum CHO content of mice; C. the serum HDL content of mice; and D. the serum LDL content of mice in each group. #p<0.01, #p<0.05 compared with the blank control group, *p<0.05 compared with the model group.
[0103] Results of four blood lipid profiles showed that compared with the control group of mice fed a regular diet, the high-fat diet group had serum TG, CHO, and LDL levels increased by 169% (P < 0.01), 26.1% (P < 0.05), and 22.8%, respectively; HDL levels decreased by 0.2%, with no significant differences. Compared with the model group, TG levels decreased by 9.9%, 13.5%, 29.6% (P < 0.05), and 8.2%, respectively, in the low-, medium-, and high-dose groups of 100Da-2000Da fermentation products and the statin group; and CHO levels decreased by 2.4%, 2.8%, 9.8%, and 2.5%, respectively, in the low-, medium-, and high-dose groups of small molecule peptides and the statin group, with no significant differences. The HDL levels of mice in the low-, medium-, and high-dose small peptide groups, as well as the statin group, increased by 17.4% (P < 0.05), 18.6% (P < 0.05), 29.9% (P < 0.05), and 14.7%, respectively. The LDL levels of mice in the low-, medium-, and high-dose small peptide groups, as well as the statin group, decreased by 4.6%, 10.9%, 17.9%, and 14.8%, respectively, but the differences were not significant. This suggests that 100Da-2000Da fermentation products can effectively lower serum total cholesterol, triglycerides, and low-density lipoprotein levels, and increase serum high-density lipoprotein levels.
[0104] Pathological sections of mouse livers showed that the normal control group exhibited normal liver tissue structure and cellular morphology, with regular cell arrangement and no fatty vacuoles. However, the model group exhibited swollen liver cells and varying degrees of diffuse hepatic steatosis, with multiple vacuoles and inflammatory cell infiltration. Compared with the model group, the statin group and the low, medium, and high dose groups of the 100Da-2000Da fermentation product all showed varying degrees of improvement in liver steatosis, with the high-dose group achieving results comparable to those of the statin group.
[0105] In summary, the 100Da-2000Da fermentation product has excellent lipid-lowering and fatty liver treatment effects, and can achieve the effect of statins. However, the fermentation product of the present invention has no toxic side effects and has a broader application prospect.
[0106] Experiment 5: Lipid-lowering therapeutic trial of fermentation products A, B, C, and D
[0107] Experimental Methods: Sixty male Kunming mice, weighing 20 ± 2 g, were randomly divided into six groups, with 10 mice in each group. Each of the experimental groups, fermentation product A, fermentation product B, fermentation product C, and fermentation product D, received 50 mg of fermentation product per mouse via gavage. A statin-positive group received 0.1 mg per mouse, and a fatty liver model group and a normal control group were also administered. Except for the normal control group, which received a standard diet, all other groups were fed a high-fat diet at 20–25°C for four weeks, with daily gavage administration. The fatty liver model group and the normal control group received an equal volume of saline. Previous studies have shown that fermentation products have the most significant effect on reducing triglyceride (TG) levels, so TG was selected as the observational indicator. The results are shown in Table 3.
[0108] Table 3 Changes of blood lipid indexes in different groups of mice before and after the experiment
[0109] Group TG (mmol / L) Normal group 0.48±0.11 Model group 1.63±0.24 Statin group 1.27±0.16** Fermentation product A group 1.68±0.21 Fermentation product B group 1.51±0.14 Fermentation product C group 1.43±0.12** Fermentation product D group 1.02±0.09*
[0110] Compared with the model group**: P < 0.01 indicates extremely significant difference
[0111] The results in Table 3 show that compared with the model group, the TG content of fermentation product A, fermentation product B and fermentation product C groups did not decrease significantly, while the TG content of fermentation product D group decreased significantly, even exceeding that of the statin group, which is a standard drug for lowering blood lipids.
[0112] Experiment 6: Further lipid-lowering treatment trial of fermentation product D with a molecular weight of 100Da-2000Da
[0113] The 100-2000 Da fermentation product was subjected to non-separating membranes of 1500 Da, 1000 Da, and 100 Da, and spray-dried to yield three fermentation products with molecular weights of 100-1000 Da, 1000-1500 Da, and 1500-2000 Da. The same hyperlipidemia model experiments as in Experiment 5 were conducted in mice, with additional observation of Oil Red O-stained liver pathological sections.
[0114] Table 4 Changes of blood lipid indexes in different groups of mice before and after the experiment
[0115] Group TG (mmol / L) Normal group 0.59±0.23 Model group 1.81±0.31 Statin group 1.17±0.27** 1500Da-2000Da fermentation product experimental group 1.19±0.36 1000Da-1500Da fermentation product experimental group 1.12±0.33* 100Da-1000Da fermentation product experimental group 0.81±0.12**
[0116] Compared with the model group**: P < 0.01 indicates extremely significant difference
[0117] The results in Table 4 show that compared with the model group, the 100Da-1000Da fermentation product group, the 1000Da-1500Da fermentation product group, and the 1500Da-2000Da fermentation product group all showed significant decreases, all exceeding the statin group. Among them, the 100Da-1000Da fermentation product group showed the most significant decrease in TG content.
[0118] As shown in Figure 4, liver pathology sections of mice in the model control group stained red, with fat particles filling the entire liver tissue. Compared to the model group, liver cells in the 100Da-1000Da fermentation product group showed virtually no red areas, demonstrating a lack of fat particle accumulation. This demonstrates that the 100Da-1000Da fermentation product has the most significant lipid-lowering and fatty liver treatment effects.
[0119] Experiment 7: Amino acid sequence identification of fermentation product D with a molecular weight of 100Da-2000Da
[0120] Given the significant lipid-lowering and fatty liver treatment effects of fermentation product components with molecular weights between 200 and 1000 Da, the spray-dried fermentation product was subjected to amino acid sequence mass spectrometry analysis. The analysis service was provided by Sangon Biotech (Shanghai) Co., Ltd. The experimental steps were as follows:
[0121] (1) Sample processing: Take fermentation products with a molecular weight of 100Da-1000Da and dissolve them in washing buffer (0.1% FA, 2% ACN); transfer the sample solution to a 10KD ultrafiltration centrifuge tube and centrifuge at 12000g for 10 min; desalt the ultrafiltration solution using a C18 desalting column; elute the sample with elution buffer (0.1% FA, 60% ACN), and transfer the elution solution to a new EP tube; centrifuge and concentrate the eluted sample to dryness for mass spectrometry analysis; redissolve it in 100uL Nano-LC mobile phase A (0.1% formic acid / water), and then directly bottle it for detection.
[0122] (2) LC-MS / MS analysis: After desalting, the sample was centrifuged and dried, then redissolved in 100 μL of Nano-LC mobile phase A (0.1% formic acid / water) and loaded into a bottle for online LCMS analysis. The dissolved sample was loaded onto a nano Viper C18 pre-column (3 μm, 100 Å) at a volume of 2 μL, and then desalted with a 20 μL volume. The liquid phase was an Easy nLC1200 nanoliter liquid phase system (ThermoFisher, USA). The sample was desalted and retained on the pre-column before being separated on the analytical column. The analytical column specifications were a C18 reversed-phase column (Acclaim PepMap RSLC, 75 μm × 25 cm C18-2 μm 100 Å). The gradient used in the experiment was from 5% to 38% of mobile phase B (80% acetonitrile, 0.1% formic acid) within 60 min. The mass spectrometer used a ThermoFisher Q Exactive system (ThermoFisher, USA) combined with a nanospray Nano Flex ion source (ThermoFisher, USA), with a spray voltage of 1.9 kV and an ion transfer tube heating temperature of 275°C. The mass spectrometer scanning mode was data-dependent acquisition mode (Data Dependent Analysis, DDA), with a primary mass spectrometer scanning resolution of 70,000, a scanning range of 100-1500 m / z, and a maximum injection time of 100 ms. A maximum of 20 secondary spectra with charges of 1+ to 3+ were collected in each DDA cycle, and the maximum injection time of secondary mass spectrometer ions was 50 ms. The collision cell energy (high-energy collision-induced dissociation, HCD) was set to 28 eV, applicable to all precursor ions, and the dynamic exclusion was set to 6 seconds.
[0123] (3) Database search analysis and results: The original raw spectrum files collected by mass spectrometry were processed and searched using PEAKS Studio 8.5 (Bioinformatics Solutions Inc. Waterloo, Canada). The database was the target species protein database downloaded from Uniprot. The search parameters were set as follows: the mass tolerance of the primary mass spectrometry was 10 ppm, and the secondary mass spectrometry was 0.05 Da. The variable modifications were oxidation (M), acetylation (Protein N-term), deamidation (NQ), pyro-glu from E, and pyro-glu from Q.
[0124] Mass spectrometry analysis revealed a total of 180 amino acid sequences. The lipid-lowering effect may be present in these 180 amino acid sequences, with the potential for multiple sequences or a single sequence acting in concert.
[0125] It should be noted that fermentation product A is used in the preparation of health foods that assist in thrombolysis or medicines for treating thrombolysis, fermentation product B is used in the preparation of health foods or medicines for improving immunity, fermentation product C is used in the preparation of health foods that assist in lowering blood pressure or medicines for treating lowering blood pressure, and fermentation product D is used in the preparation of health foods that assist in lowering blood lipids and treating fatty liver or medicines for treating hyperlipidemia and treating fatty liver.
[0126] Appendix: 180 amino acid sequences
[0127] It is understandable that those skilled in the art can make equivalent substitutions or changes based on the technical solution and inventive concept of this application, and all these changes or substitutions should fall within the scope of protection of the claims attached to this application.
Claims
1. A method for preparing a Bacillus subtilis fermentation fractionated product, comprising: Step 1), preparing a fermentation medium; Step 2), inoculating the Bacillus subtilis strain into the fermentation medium of step 1) to obtain a seed solution; Step 3), inoculating the seed liquid obtained in step 2) into the fermentation medium at an inoculation rate of 1%-5% to obtain a fermentation liquid, wherein the fermentation conditions are: fermentation time of 18-22 hours, fermentation temperature of 36-38° C., and dissolved oxygen content of 20-40% in the fermentation environment; Step 4), after the fermentation is completed, the fermentation liquid obtained in step 3) is separated to obtain bacterial cells and fermentation liquid; Step 5), the fermentation broth obtained in step 4) is fractionated and separated to collect a variety of fermentation products with different molecular weight ranges, namely, fermentation product A with a molecular weight greater than 10,000 Da, fermentation product B with a molecular weight of 6,000 Da-10,000 Da, fermentation product C with a molecular weight of 2,000 Da-6,000 Da, and fermentation product D with a molecular weight of 100 Da-2,000 Da.
2. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 1, wherein: In the step 1), the fermentation medium contains 1%-5% by mass of a nitrogen source, 2%-4% by mass of glucose, and 0.01%-0.1% by mass of calcium sulfate.
3. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 2, wherein: The nitrogen source is soybean components.
4. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 1, wherein: In the step 2), the fermentation temperature is 35-40° C., the shaking speed is 100-500 r / min, and the culture time is 15-20 h.
5. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 4, wherein: Before inoculating the Bacillus subtilis strain into the fermentation medium in step 1), activate it with a fresh slant for 18-24 hours, and pick a loop of Bacillus subtilis cells from the slant for inoculation.
6. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 1, wherein: In step 4), the fermentation liquid obtained in step 3) is separated by a tubular centrifuge, the bacterial sludge is collected, mixed with water at a weight ratio of 1:20, 10% maltodextrin is added, and spray drying is performed to obtain bacterial cells.
7. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 6, wherein: In step 4), the drying process is: inlet air temperature 155°C, outlet air temperature 82°C, and feed speed 25r / min.
8. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 1, wherein: In step 5), the fermentation liquid obtained in step 4) is separated and collected by a separation process to obtain a plurality of fermentation products with different molecular weight ranges, specifically including: The fermentation liquid is concentrated by a 10000Da separation membrane ultrafiltration device to obtain a concentrated liquid A, and the concentrated liquid A is vacuum freeze-dried or spray-dried to obtain a fermentation product A with a molecular weight greater than 10000Da; The permeate obtained by ultrafiltration of the 10000Da separation membrane in the previous step is concentrated by a 6000Da separation membrane ultrafiltration device to obtain a concentrate B, and the concentrate B is subjected to vacuum freeze drying or spray drying to obtain a fermentation product B with a molecular weight of 6000Da-10000Da; The permeate obtained by ultrafiltration of the 6000Da separation membrane in the previous step is concentrated by a 2000Da separation membrane ultrafiltration device to obtain a concentrated solution C, and the concentrated solution C is vacuum freeze-dried or spray-dried to obtain a fermentation product C with a molecular weight of 2000Da-6000Da; The permeate from the 2000Da separation membrane ultrafiltration in the previous step is concentrated by a 100Da separation membrane ultrafiltration device to obtain a concentrated solution D, and the concentrated solution D is subjected to vacuum freeze drying or spray drying to obtain a fermentation product D with a molecular weight of 100Da-2000Da.
9. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 8, wherein: In the step 5), the permeate concentrated by the 100Da separation membrane ultrafiltration device can be used to prepare the fermentation medium.
10. A method for preparing a fractionated product of Bacillus subtilis fermentation, comprising: Step 1), preparing a fermentation medium; Step 2), inoculating the Bacillus subtilis strain into the fermentation medium of step 1) to obtain a seed solution; Step 3), inoculating the seed liquid obtained in step 2) into the fermentation medium at an inoculation rate of 1%-5% for fermentation to obtain a fermentation liquid; Step 4), after the fermentation is completed, the fermentation liquid obtained in step 3) is separated to obtain bacterial cells and fermentation liquid; Step 5), the fermentation broth obtained in step 4) is fractionated and separated to collect a variety of fermentation products with different molecular weight ranges, namely, fermentation product A with a molecular weight greater than 10,000 Da, fermentation product B with a molecular weight of 6,000 Da-10,000 Da, fermentation product C with a molecular weight of 2,000 Da-6,000 Da, and fermentation product D with a molecular weight of 100 Da-2,000 Da.
11. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 10, wherein: In the step 1), the fermentation medium contains 1%-5% by mass of a nitrogen source, 2%-4% by mass of glucose, and 0.01%-0.1% by mass of calcium sulfate.
12. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 2, wherein: The nitrogen source is soybean components.
13. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 10, wherein: In the step 2), the fermentation temperature is 35-40° C., the shaking speed is 100-500 r / min, and the culture time is 15-20 h.
14. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 13, wherein: Before inoculating the Bacillus subtilis strain into the fermentation medium in step 1), activate it with a fresh slant for 18-24 hours, and pick a loop of Bacillus subtilis cells from the slant for inoculation.
15. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 10, wherein: In step 4), the fermentation liquid obtained in step 3) is separated by a tubular centrifuge, the bacterial sludge is collected, mixed with water at a weight ratio of 1:20, 10% maltodextrin is added, and spray drying is performed to obtain bacterial cells.
16. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 15, wherein: In step 4), the drying process is: inlet air temperature 155°C, outlet air temperature 82°C, and feed speed 25r / min.
17. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 10, wherein: In step 5), the fermentation liquid obtained in step 4) is separated and collected by a separation process to obtain a plurality of fermentation products with different molecular weight ranges, specifically including: The fermentation liquid is concentrated by a 10000Da separation membrane ultrafiltration device to obtain a concentrated liquid A, and the concentrated liquid A is vacuum freeze-dried or spray-dried to obtain a fermentation product A with a molecular weight greater than 10000Da; The permeate obtained by ultrafiltration of the 10000Da separation membrane in the previous step is concentrated by a 6000Da separation membrane ultrafiltration device to obtain a concentrate B, and the concentrate B is subjected to vacuum freeze drying or spray drying to obtain a fermentation product B with a molecular weight of 6000Da-10000Da; The permeate obtained by ultrafiltration of the 6000Da separation membrane in the previous step is concentrated by a 2000Da separation membrane ultrafiltration device to obtain a concentrated solution C, and the concentrated solution C is vacuum freeze-dried or spray-dried to obtain a fermentation product C with a molecular weight of 2000Da-6000Da; The permeate from the 2000Da separation membrane ultrafiltration in the previous step is concentrated by a 100Da separation membrane ultrafiltration device to obtain a concentrated solution D, and the concentrated solution D is subjected to vacuum freeze drying or spray drying to obtain a fermentation product D with a molecular weight of 100Da-2000Da.
18. The method for preparing the fractionated product of Bacillus subtilis fermentation according to claim 17, wherein: In the step 5), the permeate concentrated by the 100Da separation membrane ultrafiltration device can be used to prepare the fermentation medium.
19. A fractionated product of Bacillus subtilis fermentation, wherein: The Bacillus subtilis fermentation fractionated product is prepared by the preparation method of the Bacillus subtilis fermentation fractionated product described in claim 1.
20. The Bacillus subtilis fermentation fractionated product according to claim 19, wherein It includes fermentation product A with a molecular weight greater than 10,000 Da, fermentation product B with a molecular weight of 6,000 Da-10,000 Da, fermentation product C with a molecular weight of 2,000 Da-6,000 Da, and fermentation product D with a molecular weight of 100 Da-2,000 Da.
Citation Information
Patent Citations
Bacillus subtilis novel bacterial strain and its usage in preparation of medicament for treating thrombus disease
CN101316608A
Chickpea natto and making method and application of chickpea natto
CN102763815A
Method for preparing soybean peptide by fermenting soybean meal by bacillus subtilis ZC1
CN107574203A
Method for extracting antibacterial peptide from fermentation liquid
CN108410941A
Extraction method of lipid lowering peptide prepared through celery seed fermentation
CN109355335A
